Files and links (2)
Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs338.13 kB
Published (Version of record)CC BY-NC V3.0, Open Access
Published (Version of record)CC BY-NC V3.0, Open
Journal article
Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs
Veterinary medicine (Auckland), Vol.2016(7), pp.123-131
31/08/2016
PMCID: PMC6044797
PMID: 30050845
Metrics
3 Record Views
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Abstract
Investigation into the pharmacokinetic profile of esomeprazole was conducted using eight healthy dogs after intravenous (IV) and oral (po) administration in a two-part randomized crossover study. The dogs were fasted for a minimum of 12 hours and then received esomeprazole either intravenously (dose range 0.93–1.48 mg/kg) or orally using an enteric-coated formulation (dose range 0.95–1.50 mg/kg). After a 1-week washout period, the dogs received an alternative treatment. Serial blood samples were collected at predetermined time points, and plasma esomeprazole concentrations were determined by using ultra-high-performance liquid chromatography–mass spectrometry. Noncompartmental pharmacokinetic analyses were performed. Then, the area under the plasma concentration/time curve (AUC) and maximal plasma concentration (Cmax) values were normalized to a 1.0 mg/kg dose of esomeprazole, that is, AUC/dose. Median (range) dose-normalized peak plasma concentration (Cmax) values for the IV and po formulations were 4.06 µg/mL (2.47–4.57 µg/mL) and 1.04 µg/mL (0.31–1.91 µg/mL), respectively. The median (range) time-to-peak concentration (Tmax) for the po formulation was 105 minutes (45–360 minutes). Median (range) plasma terminal half-life (t½) was 45.56 minutes (39.43–64.20 minutes) for the IV formulation and 63.97 minutes (44.02–109.94 minutes) for the enteric-coated po formulation. The median (range) po bioavailability was 63.33% (32.26%–79.77%). Clinically, both po and IV formulations were well tolerated with minimal side effects observed.
Details
- Title
- Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs
- Creators
- Emily K Cook - University of QueenslandNana Satake - University of QueenslandBen W Sykes - University of QueenslandEmma L Bennett - University of QueenslandPaul C Mills - University of Queensland
- Publication Details
- Veterinary medicine (Auckland), Vol.2016(7), pp.123-131
- Publisher
- Dove Medical Press
- Identifiers
- 991013176798502368
- Copyright
- © 2016 The Author(s). This work is published and licensed by Dove Medical Press Limited. Creative Commons Attribution - Non Commercial (unported, v3.0) License.
- Academic Unit
- Faculty of Science and Engineering
- Language
- English
- Resource Type
- Journal article